Published in Stat Med on January 12, 2012
Early termination of a two-stage study to develop and validate a panel of biomarkers. Stat Med (2012) 1.09
Conditionally unbiased estimation in phase II/III clinical trials with early stopping for futility. Stat Med (2013) 1.03
Conditionally unbiased and near unbiased estimation of the selected treatment mean for multistage drop-the-losers trials. Biom J (2013) 0.93
Two-stage biomarker panel study and estimation allowing early termination for futility. Biostatistics (2015) 0.81
Accounting for selection and correlation in the analysis of two-stage genome-wide association studies. Biostatistics (2016) 0.79
Correcting for bias in the selection and validation of informative diagnostic tests. Stat Med (2015) 0.77
Unbiased estimation of biomarker panel performance when combining training and testing data in a group sequential design. Biometrics (2016) 0.75
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Quantifying and comparing the predictive accuracy of continuous prognostic factors for binary outcomes. Biostatistics (2004) 1.98
Time-dependent Predictive Values of Prognostic Biomarkers with Failure Time Outcome. J Am Stat Assoc (2008) 1.65
Conditional estimation of sensitivity and specificity from a phase 2 biomarker study allowing early termination for futility. Stat Med (2009) 1.60
Exact confidence intervals following a group sequential test. Biometrics (1984) 1.56
Group sequential design for comparative diagnostic accuracy studies. Stat Med (2003) 1.48
Nonparametric and semiparametric group sequential methods for comparing accuracy of diagnostic tests. Biometrics (2008) 1.35
Group sequential design for comparative diagnostic accuracy studies: implications and guidelines for practitioners. Med Decis Making (2004) 1.18
Methodological issues with adaptation of clinical trial design. Pharm Stat (2006) 0.95
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst (2005) 13.00
Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2006) 9.91
Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res (2002) 7.11
Association between body-mass index and risk of death in more than 1 million Asians. N Engl J Med (2011) 6.89
Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst (2008) 6.79
Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res (2008) 6.47
Integrating the predictiveness of a marker with its performance as a classifier. Am J Epidemiol (2007) 4.59
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
Evaluating the predictiveness of a continuous marker. Biometrics (2007) 3.54
Combining several screening tests: optimality of the risk score. Biometrics (2002) 3.34
Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem (2002) 3.05
Lung cancer risk among female textile workers exposed to endotoxin. J Natl Cancer Inst (2007) 2.87
5-year urinary and sexual outcomes after radical prostatectomy: results from the prostate cancer outcomes study. J Urol (2005) 2.72
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res (2013) 2.70
A data-analytic strategy for protein biomarker discovery: profiling of high-dimensional proteomic data for cancer detection. Biostatistics (2003) 2.69
Distribution-free ROC analysis using binary regression techniques. Biostatistics (2002) 2.64
SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem (2007) 2.38
A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev (2010) 2.36
Occupational risk factors for esophageal and stomach cancers among female textile workers in Shanghai, China. Am J Epidemiol (2006) 2.27
Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. Clin Chem (2007) 2.23
Presence of simian virus 40 DNA sequences in human lymphomas. Lancet (2002) 2.21
5-year urinary and sexual outcomes after radical prostatectomy: results from the Prostate Cancer Outcomes Study. J Urol (2008) 2.16
Ulcerative colitis is a disease of accelerated colon aging: evidence from telomere attrition and DNA damage. Gastroenterology (2008) 2.14
Evaluating markers for selecting a patient's treatment. Biometrics (2004) 2.11
Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene (2005) 2.07
Development of common data elements: the experience of and recommendations from the early detection research network. Int J Med Inform (2003) 2.04
Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer (2003) 2.01
Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology (2011) 1.94
General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes study. J Clin Oncol (2003) 1.91
Associations of body mass index, smoking, and alcohol consumption with prostate cancer mortality in the Asia Cohort Consortium. Am J Epidemiol (2015) 1.87
Clinical utility of five genetic variants for predicting prostate cancer risk and mortality. Prostate (2009) 1.83
An Automated Peak Identification/Calibration Procedure for High-Dimensional Protein Measures From Mass Spectrometers. J Biomed Biotechnol (2003) 1.73
Biases introduced by choosing controls to match risk factors of cases in biomarker research. Clin Chem (2012) 1.69
A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus. Cancer Res (2009) 1.65
FDR-controlling testing procedures and sample size determination for microarrays. Stat Med (2005) 1.64
Meat intake and cause-specific mortality: a pooled analysis of Asian prospective cohort studies. Am J Clin Nutr (2013) 1.61
Conditional estimation of sensitivity and specificity from a phase 2 biomarker study allowing early termination for futility. Stat Med (2009) 1.60
A controlled, household-randomized, open-label trial of the effect that treatment of Helicobacter pylori infection has on iron deficiency in children in rural Alaska. J Infect Dis (2006) 1.59
Multiple independent genetic variants in the 8q24 region are associated with prostate cancer risk. Cancer Epidemiol Biomarkers Prev (2008) 1.58
Semiparametric methods for evaluating risk prediction markers in case-control studies. Biometrika (2009) 1.57
Application of the time-dependent ROC curves for prognostic accuracy with multiple biomarkers. Biometrics (2006) 1.57
The sensitivity and specificity of markers for event times. Biostatistics (2005) 1.56
Antibody microarray profiling reveals individual and combined serum proteins associated with pancreatic cancer. Cancer Res (2005) 1.55
Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. J Clin Oncol (2008) 1.55
Body mass index and diabetes in Asia: a cross-sectional pooled analysis of 900,000 individuals in the Asia cohort consortium. PLoS One (2011) 1.55
Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers. PLoS Med (2007) 1.52
Reproducible two-dimensional capillary electrophoresis analysis of Barrett's esophagus tissues. Anal Chem (2006) 1.49
[-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J Urol (2008) 1.47
Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository. Urology (2009) 1.46
Telomere length in the colon declines with age: a relation to colorectal cancer? Cancer Epidemiol Biomarkers Prev (2006) 1.42
Modeling, estimation and validation of cotton dust and endotoxin exposures in Chinese textile operations. Ann Occup Hyg (2006) 1.41
Cancer prevention behaviors and socioeconomic status among Hispanics and non-Hispanic whites in a rural population in the United States. Cancer Causes Control (2002) 1.41
Extended lifespan of Barrett's esophagus epithelium transduced with the human telomerase catalytic subunit: a useful in vitro model. Carcinogenesis (2003) 1.39
Estimating disease prevalence in two-phase studies. Biostatistics (2003) 1.36
Glycosylation variants of mucins and CEACAMs as candidate biomarkers for the diagnosis of pancreatic cystic neoplasms. Ann Surg (2010) 1.35
Knowledge, attitudes, and behaviors of hepatitis B screening and vaccination and liver cancer risks among Vietnamese Americans. J Health Care Poor Underserved (2007) 1.33
Biomarker evaluation and comparison using the controls as a reference population. Biostatistics (2008) 1.32
Prevalidation of salivary biomarkers for oral cancer detection. Cancer Epidemiol Biomarkers Prev (2012) 1.30
Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality. Cancer Epidemiol Biomarkers Prev (2011) 1.28
Retracted DNA methylation profiles of lymphoid and hematopoietic malignancies. Clin Cancer Res (2004) 1.26
Retracted Aberrant promoter methylation of multiple genes during multistep pathogenesis of colorectal cancers. Int J Cancer (2006) 1.25
Ulcerative colitis-associated colorectal cancer arises in a field of short telomeres, senescence, and inflammation. Cancer Res (2011) 1.23
A multiparametric panel for ovarian cancer diagnosis, prognosis, and response to chemotherapy. Clin Cancer Res (2007) 1.22
Vitamin D pathway gene variants and prostate cancer prognosis. Prostate (2010) 1.20
Application of a methylation gene panel by quantitative PCR for lung cancers. Cancer Lett (2006) 1.19
Serum protein expression profiling for cancer detection: validation of a SELDI-based approach for prostate cancer. Dis Markers (2004) 1.18
Semiparametric models of time-dependent predictive values of prognostic biomarkers. Biometrics (2009) 1.17
Evaluation of known oncoantibodies, HER2, p53, and cyclin B1, in prediagnostic breast cancer sera. Cancer Prev Res (Phila) (2012) 1.15
Data reduction using a discrete wavelet transform in discriminant analysis of very high dimensionality data. Biometrics (2003) 1.12
Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features. PLoS One (2008) 1.12
Early termination of a two-stage study to develop and validate a panel of biomarkers. Stat Med (2012) 1.09
Genome-wide association study identifies a genetic variant associated with risk for more aggressive prostate cancer. Cancer Epidemiol Biomarkers Prev (2011) 1.08
Estimating the capacity for improvement in risk prediction with a marker. Biostatistics (2008) 1.08
Updating risk prediction tools: a case study in prostate cancer. Biom J (2011) 1.08
Optimized normalization for antibody microarrays and application to serum-protein profiling. Mol Cell Proteomics (2005) 1.08
Occupational exposures and breast cancer among women textile workers in Shanghai. Epidemiology (2007) 1.07
Enhanced discrimination of malignant from benign pancreatic disease by measuring the CA 19-9 antigen on specific protein carriers. PLoS One (2011) 1.07
Statin use in relation to prostate cancer outcomes in a population-based patient cohort study. Prostate (2013) 1.06
An intervention study on screening for breast cancer among single African-American women aged 65 and older. Prev Med (2002) 1.06
Analysis of serum haptoglobin fucosylation in hepatocellular carcinoma and liver cirrhosis of different etiologies. J Proteome Res (2014) 1.05
Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk. Am J Epidemiol (2010) 1.02
Genetic polymorphisms in inflammation pathway genes and prostate cancer risk. Cancer Epidemiol Biomarkers Prev (2011) 1.02
Performance of a single assay for both type III and type VI TMPRSS2:ERG fusions in noninvasive prediction of prostate biopsy outcome. Clin Chem (2008) 1.01
Baseline data and design for a randomized intervention study of dietary change in religious organizations. Prev Med (2004) 1.00
Vitamin D receptor gene polymorphisms and prostate cancer risk. Prostate (2004) 1.00
Increased plasma levels of the APC-interacting protein MAPRE1, LRG1, and IGFBP2 preceding a diagnosis of colorectal cancer in women. Cancer Prev Res (Phila) (2012) 0.99
Polymorphisms in the glutathione S-transferase M1, T1, and P1 genes and prostate cancer prognosis. Prostate (2006) 0.99
Lung adenocarcinoma of never smokers and smokers harbor differential regions of genetic alteration and exhibit different levels of genomic instability. PLoS One (2012) 0.99
A polymorphism in the CYP17 gene and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev (2002) 0.98
Assessing risk prediction models in case-control studies using semiparametric and nonparametric methods. Stat Med (2010) 0.98
Evaluating prognostic accuracy of biomarkers under competing risk. Biometrics (2011) 0.98
When does combining markers improve classification performance and what are implications for practice? Stat Med (2013) 0.96
Noninvasive saliva-based EGFR gene mutation detection in patients with lung cancer. Am J Respir Crit Care Med (2014) 0.95
The early detection research network surface-enhanced laser desorption and ionization prostate cancer detection study: A study in biomarker validation in genitourinary oncology. Urol Oncol (2004) 0.95
CYP17 polymorphisms and prostate cancer outcomes. Prostate (2010) 0.95
Presence of simian virus 40 DNA sequences in human lymphoid and hematopoietic malignancies and their relationship to aberrant promoter methylation of multiple genes. Cancer Res (2004) 0.95